Podcasts about lombardi cancer center

Mona Jhaveri is a biotech scientist and entrepreneur notable for her approaches to cancer research, detection, and funding. She earned her Bachelor's Degree from SUNY Binghamton and her Doctorate in Biochemistry from the Bowman Gray School of Medicine of Wake Forest University, trained as a post-doctoral fellow at the National Cancer Institute, was granted the SPORE Fellowship Award for Breast Cancer Research at the Lombardi Cancer Center of Georgetown University, and received the Cartier Women's Initiative Award. She is the Founder of Foligo Therapeutics Inc., the Founder and Executive Director of Sound Affects, and the Founder, Executive Director, and Chairman of the Board at Music Beats Cancer. Mona makes her home in Ridgefield, Connecticut.

Joseph Treat, MD, is a Professor of the Department of Hematology/Oncology, Vice Chair of Education and Medical Director for Ambulatory Care at Fox Chase Cancer Center. Dr. Treat completed his medical school from Temple University and residency in Internal Medicine from Georgetown University Hospital where he stayed to pursue an Oncology fellowship at the Lombardi Cancer Center. He has dedicated his clinical practice to mesothelioma and lung cancer for the past 20 years and has published extensively on these topics, including widely read reviews on popular chemotherapeutic agents used in the treatment of lung cancer. Science and Empathy being distinct opposites is a common misconception; Dr. Treat says: "Medicine is a gift that allows us to combine the scientific method with empathy. Eliminate the grocery list mentality and be empathetic." Join us as we listen to anecdotes from Dr. Treat's life and identify the essentials of medicine and mentorship to make the leap from good to great. Pearls of Wisdom:   1. Patients can understand when you are simply ticking off the grocery list of medical procedures. To become a GREAT physician, you must employ empathy in your practice. 2. Mentorship is an active process. It's not magic. You must deliberately reach out to potential mentors by being an enthusiastic mentee. 3. Getting things done quickly is a critical quality. It's an overt indicator for competence and determination. Always be swift in completing tasks.

HL7 has been working to advance FHIR - Fast Healthcare Interoperability Resources Platform standard since 2012. In 2014 healthcare industry players started to band together in the Argonaut project which was the first implementation community comprising leading technology vendors and provider organizations stakeholders. Since that time, several consortiums of health industry leaders have rallied around various health IT initiatives such as health payer initiatives, puplic health and health equity, infrastructure, and research initiatives. There are now eight FHIR accelerators who have published implementation guides that provide important documentation on how technology builders should use the FHIR resources within their systems to advance data sharing. These implementation guides have become the foundation for use of the standard as prescribed in Interoperability rules set forth by the Center for Medicare and Medicaid Services and the Office of the National Coordinator for Health IT. Now that so many implementation guides are near complete, the HL7 organization has added three new executive positions to support standards implementation in the new HL7 Implementation Division. So today we will talk to the spearheads of the Implementation Division to better understand how this expanded focus will impact the business of healthcare. Dr. Charles Jaffe is the CEO of HL7. He completed his medical training at Johns Hopkins and Duke Universities and post-doctoral training at NIH and the Lombardi Cancer Center. He served in various academic positions in the Departments of Medicine and in the School of Engineering and has worked in healthcare technology for more than 30 years.. Dr. Jaffe has led the charge at HL7 since 2007. Viet Nguyen, MD, will head the standards implementation division as chief standards implementation officer alongside Diego Kaminker who will fill the role of deputy chief standards implementation officer. Viet is an internist, pediatrician, and clinical informaticist who has held leadership roles such as chief medical officer and chief medical information officer at Leidos Corporation, Lockheed-Martin, and Systems Made Simple. HL7 selected Kaminker as the deputy chief standards implementation officer. He is the founder and owner of Kern IT with specialties in integration, software development, and project management. Kaminker has been a member of the HL7 community for twenty years and has served multiple terms as the chair of HL7 Argentina as well as an affiliate director of the HL7 International board of directors. Throughout his career, Kaminker has defined, implemented, and maintained hundreds of HL7 interoperability projects. On this episode of the podcast this powerhouse leadership team talks about their strategies for engaging more healthcare stakeholders in the implementation process to better inform those building the specification.

On this episode of Health Care Today, Dr. Louis Meyers speaks with Dr. John Marshall. Dr. Marshall is the Chief of Hematology and Oncology at the Lombardi Cancer Center in Washington D.C. He'll talk about GI Cancers, of which he is one of the nations leading experts. Dr. Marshall will also talk about the book he and his wife recently authored.

On this episode of Health Care Today, Dr. Louis Meyers speaks with Dr. John Marshall. Dr. Marshall is the Chief of Hematology and Oncology at the Lombardi Cancer Center in Washington D.C. He'll talk about GI Cancers, of which he is one of the nations leading experts. Dr. Marshall will also talk about the book he and his wife recently authored.

Dr. Mona Jhaveri, the Founder and Executive director at Music Beats Cancer. She launched Music Beats Cancer to address the “Valley of Death,” the growing gap in funding that constrains the translation of cancer research discoveries into clinical applications. As cancer affects millions around the globe each year, efforts to cure this disease have largely focused on cancer research rather than cancer product development. Dr. Jhaveri believes that the key to bridging the Valley of Death is to: Raise public awareness about the Valley of Death and its impact on our progress on the war against cancer; Create a funding platform that empowers the public to directly and transparently support the development of cancer-fighting solutions. Dr. Jhaveri holds a doctorate in biochemistry from the Bowman Gray School of Medicine of Wake Forest University. She trained as a post-doctoral fellow at the National Cancer Institute. Dr. Jhaveri was granted the SPORE Fellowship Award for Breast Cancer Research at the Lombardi Cancer Center of Georgetown University.

Dr. Mona Jhaveri, the Founder and Executive director at Music Beats Cancer. She launched Music Beats Cancer to address the “Valley of Death,” the growing gap in funding that constrains the translation of cancer research discoveries into clinical applications. As cancer affects millions around the globe each year, efforts to cure this disease have largely focused on cancer research rather than cancer product development. Dr. Jhaveri believes that the key to bridging the Valley of Death is to: Raise public awareness about the Valley of Death and its impact on our progress on the war against cancer; Create a funding platform that empowers the public to directly and transparently support the development of cancer-fighting solutions. Dr. Jhaveri holds a doctorate in biochemistry from the Bowman Gray School of Medicine of Wake Forest University. She trained as a post-doctoral fellow at the National Cancer Institute. Dr. Jhaveri was granted the SPORE Fellowship Award for Breast Cancer Research at the Lombardi Cancer Center of Georgetown University.

Dr. Mona Jhaveri, the Founder and Executive director at Music Beats Cancer. She launched Music Beats Cancer to address the “Valley of Death,” the growing gap in funding that constrains the translation of cancer research discoveries into clinical applications. As cancer affects millions around the globe each year, efforts to cure this disease have largely focused on cancer research rather than cancer product development. Dr. Jhaveri believes that the key to bridging the Valley of Death is to: Raise public awareness about the Valley of Death and its impact on our progress on the war against cancer; Create a funding platform that empowers the public to directly and transparently support the development of cancer-fighting solutions. Dr. Jhaveri holds a doctorate in biochemistry from the Bowman Gray School of Medicine of Wake Forest University. She trained as a post-doctoral fellow at the National Cancer Institute. Dr. Jhaveri was granted the SPORE Fellowship Award for Breast Cancer Research at the Lombardi Cancer Center of Georgetown University.

— Too many potential cures for cancer disappear in a funding bottleneck. Music Beats Cancer is changing this by leveraging the power and passion of people and music to help raise funds and awareness of promising cancer innovations that would otherwise linger in the Valley of Death. Their mission is to increase the number of cancer-fighting technologies in the product development pipeline so that more solutions make it to those in need. Valeria Teles interviews Dr. Mona Jhaveri, a Founder, Executive Director, And Chairman Of The Board At Music Beats Cancer, And Speaker Dr. Mona Jhaveri launched the nonprofit to address the “Valley of Death,” the growing gap in funding that constrains the translation of cancer research discoveries into clinical applications. Prior to Music Beats Cancer, Jhaveri founded Foligo Therapeutics, Inc. in 2005 to develop and commercialize a DNA-based therapeutic compound as a potential treatment for ovarian cancer. While Foligo was able to initially attract funding from various state-run venture programs and business plan competitions, the company ultimately succumbed to the Valley of Death. Jhaveri realized that breaking this funding bottleneck was a more critical priority than Foligo and rededicated herself to Music Beats Cancer and its mission. Jhaveri holds a doctorate in biochemistry from the Bowman Gray School of Medicine of Wake Forest University. She trained as a post-doctoral fellow at the National Cancer Institute and was granted the SPORE Fellowship Award for Breast Cancer Research at the Lombardi Cancer Center of Georgetown University. She subsequently specialized in intellectual property and technology transfer while at the Ludwig Institute for Cancer Research. To learn more about Dr. Mona Jhaveri and her work, please visit: https://www.musicbeatscancer.org/     — This podcast is a quest for well-being, a quest for a meaningful life through the exploration of fundamental truths, enlightening ideas, insights on physical, mental, and spiritual health. The inspiration is Love. The aspiration is to awaken new ways of thinking that can lead us to a new way of being, being well.   

This week, The ASCO Post sat down with Dr. John Marshall, of the Lombardi Cancer Center at Georgetown University, and his wife, Liza Marshall, a former lawyer, active advocate for patients with cancer, and a breast cancer survivor.The Marshalls are the coauthors of a new book entitled Off Our Chests: A Candid Tour Through the World of Cancer, published this week by IdeaPress Publishing and named one of the “10 Books to Read in May 2021” by The Washington Post.Together, they discuss the impact of Liza's breast cancer diagnosis, how it changed their view of cancer care and the way clinicians communicate, and why their book has an important message.To listen to more podcasts from ASCO, visit asco.org/podcasts.

The latest episode of Lung Cancer Considered introduces its new hosts, Dr. Stephen Liu and Dr. Narjust Duma. Dr. Liu is an associate professor at the Lombardi Cancer Center at Georgetown University School of Medicine. Dr. Duma is an assistant professor of medicine and a thoracic oncologist at the University of Wisconsin. Get to know both Dr. Liu and Dr. Duma a little more and hear what their goals are in 2021 for Lung Cancer Considered.

The latest episode of Lung Cancer Considered focuses on lung cancer research presented at the American Society of Clinical Oncology virtual meeting this past weekend. This episode features a conversation between IASLC Chief Science Officer, Dr. Chandra Belani and Dr. Stephen Liu, associate professor at the Lombardi Cancer Center at Georgetown University School of Medicine.

For millions of people worldwide, a cancer diagnosis is a terrifying and life-changing event. But what if a diagnosis of cancer was a call to action, that allowed you inspiration and healing? What if it enabled us to mend family relationship and get a fresh perspective on life’s priorities? Better still, what if allowed you to finally sit down write about your experiences, express your feelings and cultivate courage and strength in the process? Research conducted at the Lombardi Cancer Center at Georgetown University indicates that expressive writing––dealing with ones deepest thoughts and emotions––may contribute to improved physical and emotional health. A study in The Oncologist medical journal found patients who participated in a single 20-minute writing session improved their outlook on cancer and physical quality of life. David Tabatsky’s work focuses on ways we can take control of any diagnosis and break down the fear and isolation faced by humans experiencing any kind of health crisis. His book, Write for Life provides all people affected by cancer (patients, caregivers, family, friends, medical community, etc.) the opportunity to explore personal expression through writing, enabling them to use creativity and writing as a meaningful tool in the fight against cancer.

Welcome to the ASCO Daily News podcast. I'm Lauren Davis. And joining me today is Dr. Alexander Kim, chief and residency program director of vascular and interventional radiology at Georgetown University Medical Center. He specializes in interventional oncology, and his practice is focused on locoregional cancer therapies. Dr. Kim, welcome to the podcast. Thanks for the invitation, Lauren. I'm happy to be here. Today we're talking about a somewhat new subspecialty in oncology-- interventional radiology. This can be used as both a diagnostic tool and a tool to administer therapies. How does that work? So interventional radiology is a field where we use image guidance to perform minimally invasive procedures. So all of our procedures are performed under ultrasound, or CT, or sometimes MRI. And we're able to advance needles and catheters into places that, 15, 20 years ago, we weren't able to reach. And in terms of diagnosis, this has really revolutionized cancer management. So for a patient with a nodule in in their abdomen, let's say, who previously may have had to go to the operating room for a biopsy and diagnosis, that patient now undergoes a same-day procedure in IR and just gets the CT biopsy performed. From that, it led to more and more therapies being developed, where we're now able to go in and treat various cancers in the kidney, and the liver, and lungs using the same techniques. So how new is this technology? And how has it changed the way medicine has been practiced compared with, say, 10 years ago? Interventional radiology is a subspecialty of radiology. And it actually initially was called special procedures. And that's been around since the '50s and '60s. Really, the dramatic change has really taken over in the last 10 to 15 years in terms of cancer care. And I like to think that we're one of the forefront specialties in the move towards minimally invasive procedures. So again, whereas 10 years ago a patient may have had to go to the operating room for various procedures which required a patient to stay in the hospital for an extended period of time to recover after their surgery, with treatment and diagnostic modalities that we have, this really limits their hospital stay. And I think that's probably the biggest contribution that interventional radiology has made into the field of medicine-- is really minimizing the length of stay and, in turn, the quality of life of patients who may not have that much to live with their disease. Tell me, what kind of program have you developed that your cancer center? So we have a large interventional college of practice at Georgetown. We have a large NCI-designated cancer center, the Lombardi Cancer Center, where we get a lot of patient referrals from. We are also a large transplant center. And through that, we see a lot of HCC primary liver cancer patients. And one of the things that really benefits us is, really, the collaborative group that we have who work with us. So our medical oncologist, and our surgical oncologist, and the radiation oncologist colleagues are really very pro-minimally invasive treatment. They're very local therapy friendly. So oftentimes, they're very open to different therapeutic suggestions that we bring up at our various multidisciplinary conferences. And I think that's really helped to grow our practice and helped it thrive. What are some of the challenges in creating such a program? You know, I think buy-in. Interventional radiology is a very under-recognized specialty, even within medicine. Part of our issue-- we have an identity issue. People outside of interventional radiology aren't really familiar with the things that we're capable of doing. So I think it requires a lot of effort amongst interventional radiologists who go to the multidisciplinary boards, and speak up, and say, hey, we could maybe approach this patient in this minimally invasive way. And after a while, that trust is built. So a lot of the groundwork-- having open-minded colleagues certainly helps. Absolutely. And what are some of your measures of success? In terms of the collaborative effort that we have, in terms of our overall patient management, the collaboration that we have, the open-mindedness to our input, I think, kind of defines our success within the hospital. And obviously, in terms of patient care, we want to make sure that we're at the forefront of research and producing good outcomes for the patients that we take care of. And will these procedures that you do through interventional radiology-- do they increase progression-free survival or lead to possible cure rates? Yeah, and I think a good number of our procedures do improve survival. A lot of the patient population that we see in integrative therapy is palliative. But there are more and more data that's coming out showing the potential survival improvement with our treatment. So recently, a study was published out of Europe. It's called the CLOCC trial, where they compared systemic chemotherapy alone versus chemotherapy plus ablation for patients with colorectal cancer with liver-only metastases. There was a significant survival advantage in patients who underwent ablation plus systemic chemotherapy. And in fact, 35%-- actually, 36% of those patients were alive at 9 years, which is a pretty incredible finding. And there are other studies in other disease processes that are coming out that show that these minimally invasive therapies can potentially have curative effects. We need more data like that. But the data that's coming out, I think, are very promising. That's wonderful. Again, today, my guest has been Dr. Alexander Kim. Thank you for being on our podcast today. Thank you very much. That was really fun. And to our listeners, thank you for tuning into the ASCO Daily News podcast. If you're enjoying the content, we encourage you to rate us and review us on Apple Podcast.

Dr. Louis Weiner, Director of the Lombardi Cancer Center, Board member of the Antibody Society, and co-founder of Jounce Therapeutics is an internationally recognized medical oncologist specializing in the treatment in gastrointestinal cancers. Additionally, Dr. Weiner is an accomplished researcher developing novel immunotherapy treatments for cancer, widely known for his work in antibody-based therapeutics, including the development of bi-specific antibodies.

Are  you at high risk for colon cancer? This podcast is for patients and families who would like to understand more about the known hereditary causes of colon cancer and the role of genetic counseling and testing. Topics covered include: The role of genetics in causing colon cancer The hereditary colon and uterine cancer connection What is Lynch Syndrome and how do we screen for it Dr. Taubman is a is a local expert on the hereditary aspects of cancer. He is a graduate of the City of Hope Program in Cancer Genetics and a member of the Fischer Center for Familial Cancer Research at Lombardi Cancer Center and sees patients in consultation who may be at high risk for hereditary cancers. Questions, suggestions or comments about our podcasts?  E-mail us at olneymywellness@olneymedical.com  …

On today's episode, the Cancer Support Community addresses cancer care through the winter, cold and flu season. Kim Thiboldeaux is joined by Michelle Warren, the program director at our affiliate in Gilda's Club Metro Detroit and Alice Beers, an Oncology nurse at the Lombardi Cancer Center at Georgetown University Hospital. Tune in to find out how to stay healthy and cope effectively with post-holiday fatigue.

Are you at high risk for breast or ovarian cancer? This podcast is for patients and families who would like to understand more about the known hereditary causes of breast and ovarian cancer and the role of genetic counseling. Topics covered include: The role of genetics in causing cancer The hereditary breast and ovarian cancer connection The Role of cancer genetic counseling and testing What does a negative BRCA test result really mean Dr. Taubman is a is a local expert on the hereditary aspects of cancer.  He is a graduate of the City of Hope Program in Cancer Genetics and a member of the Fischer Center for Familial Cancer Research at Lombardi Cancer Center and sees patients in consultation who may be at high risk for hereditary cancers. Questions, suggestions or comments about our podcasts?  E-mail us at olneymywellness@olneymedical.com…

On today's episode, the Cancer Support Community addresses cancer care through the winter, cold and flu season. Kim Thiboldeaux is joined by Michelle Warren, the program director at our affiliate in Gilda's Club Metro Detroit and Alice Beers, an Oncology nurse at the Lombardi Cancer Center at Georgetown University Hospital. Tune in to find out how to stay healthy and cope effectively with post-holiday fatigue.